Transcriptomics-based screening identifies pharmacological inhibition of hsp90 as a means to defer aging

dc.contributor.authorJanssens, Georges E.
dc.contributor.authorLin, Xin-Xuan
dc.contributor.authorMillán Ariño, Lluís, 1984-
dc.contributor.authorKavšek, Alan
dc.contributor.authorSen, Ilke
dc.contributor.authorSeinstra, Renée I.
dc.contributor.authorStroustrup, Nicholas
dc.contributor.authorNollen, Ellen A. A.
dc.contributor.authorRiedel, Christian G.
dc.date.accessioned2019-07-16T09:27:22Z
dc.date.available2019-07-16T09:27:22Z
dc.date.issued2019
dc.description.abstractAging strongly influences human morbidity and mortality. Thus, aging-preventive compounds could greatly improve our health and lifespan. Here we screened for such compounds, known as geroprotectors, employing the power of transcriptomics to predict biological age. Using age-stratified human tissue transcriptomes and machine learning, we generated age classifiers and applied these to transcriptomic changes induced by 1,309 different compounds in human cells, ranking these compounds by their ability to induce a "youthful" transcriptional state. Testing the top candidates in C. elegans, we identified two Hsp90 inhibitors, monorden and tanespimycin, which extended the animals' lifespan and improved their health. Hsp90 inhibition induces expression of heat shock proteins known to improve protein homeostasis. Consistently, monorden treatment improved the survival of C. elegans under proteotoxic stress, and its benefits depended on the cytosolic unfolded protein response-inducing transcription factor HSF-1. Taken together, our method represents an innovative geroprotector screening approach and was able to identify a class that acts by improving protein homeostasis.
dc.description.sponsorshipN.S. was supported by funding from the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, the CERCA Programme/Generalitat de Catalunya, and an award from the Glenn Foundation for Medical Research. E.A.A.N. was supported by the European Research Council (ERC) and the alumni chapter of Gooische Groningers facilitated by Ubbo Emmius Fonds. C.G.R. was supported by the Swedish Research Council (VR) grant 2015-03740, the COST grant BM1408 (GENiE), and an ICMC project grant
dc.format.mimetypeapplication/pdf
dc.identifier.citationJanssens GE, Lin XX, Millan-Ariño L, Kavšek A, Sen I, Seinstra RI et al. Transcriptomics-based screening identifies pharmacological inhibition of hsp90 as a means to defer aging. Cell Rep. 2019 Apr 9;27(2):467-80. DOI: 10.1016/j.celrep.2019.03.044
dc.identifier.doihttp://dx.doi.org/10.1016/j.celrep.2019.03.044
dc.identifier.issn2211-1247
dc.identifier.urihttp://hdl.handle.net/10230/42004
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofCell Reports. 2019 Apr 9;27(2):467-80
dc.rights© 2019 The Authors. This is an open access article under a CC BY license
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.otherEnvelliment
dc.subject.otherFarmacologia
dc.subject.otherGenètica
dc.titleTranscriptomics-based screening identifies pharmacological inhibition of hsp90 as a means to defer aging
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Jan_CR_Tra.pdf
Size:
3.41 MB
Format:
Adobe Portable Document Format

License

Rights